Belite Bio, Inc (BLTE)

Belite Bio, Inc (BLTE) is a healthcare company (biotechnology) based in the United States. The share price is $156.86, down 3.51% on the day, which values the company at $6.32B. Price as of 17 Nov 2026, 17:36 UTC, from Yahoo Finance.

Key facts

Share price
$156.86−3.51% today
Market value
$6.32B
200-week average
$77.68102% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Belite Bio, Inc in more detail

BLTE trades at -722.4× next year's expected earnings. It sits 102% above its 200-week average of $77.68.

In its favour: More cash than debt. Worth checking: Share count keeps rising; Thin interest cover.

2 of the superinvestors tracked here hold BLTE, including Lee Ainslie (0.6% of the portfolio), Stanley Druckenmiller (0.4% of the portfolio).

Superinvestors holding BLTE

2 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:BLTE vs LGND (Belite Bio, Inc vs Ligand Pharmaceuticals)BLTE vs RDNT (Belite Bio, Inc vs RadNet)BLTE vs SRRK (Belite Bio, Inc vs Scholar Rock Holding)BLTE vs TFX (Belite Bio, Inc vs Teleflex)BLTE vs MIRM (Belite Bio, Inc vs Mirum Pharmaceuticals)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Belite Bio, Inc (BLTE): questions and answers

What is Belite Bio, Inc's market cap?

Belite Bio, Inc is valued at $6.32B at a share price of $156.86.

Is BLTE above its 200-week moving average?

Yes. BLTE is 101.9% above its 200-week average of $77.68. Long-term investors watch that line because strong companies rarely trade below it for long.

Does BLTE pay a dividend?

Belite Bio, Inc does not currently pay a regular dividend.

Which famous investors own BLTE?

In their latest quarterly filings, Lee Ainslie (0.6% of the portfolio), Stanley Druckenmiller (0.4% of the portfolio) hold BLTE. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Belite Bio, Inc (BLTE) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BLTE

Underlying data: Yahoo Finance; company filings with the SEC.